Back to search

University of Patras

Υποδοχέας της φωσφολιπάσης Α2 και συσχέτισή του με την κλινική πορεία ασθενών με ιδιοπαθή μεμβρανώδη σπειραματονεφρίτιδα

Abstract

dc:description

Primary membranous nephropathy (MN) is the prototype of immune-mediated glomerular disease and one of the most common causes of nephrotic syndrome and chronic kidney disease worldwide. Its pathogenesis involves appearance of autoantibodies against certain glomerular membrane antigens, formation of antigenantibody complexes and subsequent deposition of these immune complexes in the membrane subepithelial surface. Research for the target antigen in human MN led to the discovery of autoantibodies against a podocyte protein which was identified as the M type phospholipase A2 receptor. The present work represents the first formal study of anti-PLA2R autoantibodies in Greek patients with MN. Our primary goals were the detection of anti-PLA2R antibodies in the serum of patients with diagnosed MN, the evaluation of parameters that could be associated with their appearance, as well as quantitative measurement and monitoring of their level alterations. The study included 65 patients who were diagnosed and treated at two distinguished nephrological centers, the Nephrology Department of the University Hospital of Patras and the Nephrology Department of the University Hospital of Thessaloniki. Measurement of antiPLA2R antibodies was carried out with a widely-used commercially available ELISA kit and the positivity threshold was defined as 20 RU/ml. According to our results, detectable or positive anti-PLA2R antibodies were found in 16 of 33 patients at the time of diagnosis (48.5%). Patients with positive anti-PLA2R antibodies were mostly women. Comparison between PLA2R-positive and negative patients at diagnosis did not reveal any differences in their demographic, clinical or histological characteristics. Baseline anti-PLA2R levels were correlated with patient outcome after immunosuppressive treatment and anti-PLA2R titer was identified as the only independent factor associated with the achievement of partial compared to complete remission (p=0.02). Furthermore, anti-PLA2R levels were positively correlated with proteinuria levels at the end of a 5-year follow up (p=0.0002). Ιn the subgroup of PLA2R-positive patients at diagnosis, higher antibody levels were significantly correlated with greater proteinuria (p=0.0001) and lower eGFR (p=0.0083) after 5 years of follow-up. These associations remained significant when the positivity threshold was set to a lower level of 2 RU/ml (p<0.0001 and p=0,0111, respectively) corresponding to higher sensitivity of the test. In 17 patients, we measured anti-PLA2R levels at random time points during their routine visits, after diagnosis and treatment initiation. At the time the blood samples were taken, the majority of patients were at complete (53%) or partial remission (23.5%) of proteinuria and they all had normal kidney function. Antibody levels ranged from 0 to 5043 RU/ml and only 23.5% were found positive. No correlation was reported between antibody positivity or titer and patient characteristics and longterm outcomes. In a different group of 14 patients, anti-PLA2R antibodies were measured in two blood samples that had been obtained at two distinct time points during their follow up. Depending on their clinical status in the corresponding time, all patients were classified in 3 groups; group A included 4 patients with nephrotic syndrome who achieved complete remission after immunosuppressive treatment; group B consisted of 5 patients with prolonged clinical remission; and in group C, antibodies were measured during clinical remission and a relapse episode in 6 patients. Despite the small number of patients, the differences between the 3 groups were profound. More specifically, antibody level alterations were considered significant in groups A and C, in which there was a change of clinical status (p=0.0448 and p=0.0379, respectively). On the contrary, titer alteration was not significant in patients with sustained remission included in group B (p=0.3781).Our main conclusions are in agreement with results of similar studies in various populations. Baseline anti-PLA2R levels are considered to have a prognostic value, as they are associated with achievement of complete remission. Moreover, they are associated with long-term disease outcome expressed as proteinuria. In the subgroup of PLA2R-positive patients, increased baseline titers have an additional strong correlation with heavier proteinuria and lower eGFR after 5 years of follow-up. Finally, repeated anti-PLA2R measurements confirm the significant correlation of antibody titers with disease clinical activity.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Provatopoulou, Simella
  • Προβατοπούλου, Σιμέλλα

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/49277

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Provatopoulou, Simella; Προβατοπούλου, Σιμέλλα. Υποδοχέας της φωσφολιπάσης Α2 και συσχέτισή του με την κλινική πορεία ασθενών με ιδιοπαθή μεμβρανώδη σπειραματονεφρίτιδα. University of Patras, 2021. http://hdl.handle.net/10442/hedi/49277